Skip to content
Services
Services
Corporate Finance
Mergers and Acquisitions
Capital Markets
Private Funds Advisory
Board Advisory Services
Financial Restructuring
Financial and Valuation Advisory
Portfolio Valuation and Fund Advisory
Transaction Opinions
Corporate Valuation Advisory Services
Transaction Advisory Services
Real Estate Valuation
Dispute Resolution Consulting
Industries
Industries
Business Services
Consumer
Energy
Financial Services
FinTech
Healthcare
Industrials
Real Estate, Lodging, and Leisure
Technology
Financial Sponsors Coverage
Insights
About Us
About Us
Transactions
Newsroom
Events
Social Commitment
Contact Us
Investor Relations
Careers
Worldwide
Worldwide
Americas
Australia
Benelux
Brazil
China
Dubai
France
Germany
Hong Kong SAR
India
Israel
Italy
Japan
Singapore
Spain
Sweden
Switzerland
United Kingdom
Search results
{{item.title}}
clear
Search results
{{item.title}}
Services
Corporate Finance
Mergers and Acquisitions
Capital Markets
Private Funds Advisory
Board Advisory Services
Financial Restructuring
Financial and Valuation Advisory
Portfolio Valuation and Fund Advisory
Transaction Opinions
Corporate Valuation Advisory Services
Transaction Advisory Services
Real Estate Valuation
Dispute Resolution Consulting
Industries
Business Services
Consumer
Energy
Financial Services
FinTech
Healthcare
Industrials
Real Estate, Lodging, and Leisure
Technology
Financial Sponsors Coverage
Insights
About Us
Transactions
Newsroom
Events
Social Commitment
Contact Us
Investor Relations
Careers
Worldwide
Americas
Australia
Benelux
Brazil
China
Dubai
France
Germany
Hong Kong SAR
India
Israel
Italy
Japan
Singapore
Spain
Sweden
Switzerland
United Kingdom
Investor Relations
Home
About Us
Transactions
TRANSACTION DETAIL
大日本住友製薬による Sunovion Pharmaceuticals Europe
のInflexion Private Equity Partnersへの売却
(大日本住友製薬へのアドバイザリー)
View All Transactions
You are about to leave Houlihan Lokey’s website
The link below leads to a website
that is not owned by Houlihan Lokey.
Continue
to the external website,
or
close the window
to remain on HL.com